

## NZX/ASX Announcement

3 March 2023

### TruScreen Raises Initial \$600,000 in Share Placement

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that further to the announcement of 17 February 2023 “Truscreen to lodge a pro rata renounceable rights issue”, the Company has received firm commitments from a number of investors for an initial Placement of 20,000,000 shares at NZ\$0.03 each to raise \$600,000, before costs.

The shares will be issued under its existing 15% placement capacity. This Placement is in addition to the Oversubscription Bookbuild which will take place on 15<sup>th</sup> and 16<sup>th</sup> March 2023.

Tony Ho Chairman commented, “*we are pleased with the strong support we have received at the start of this capital raise, and encourage shareholders to ensure their applications are completed before the closing date on 15 March 2023*”.

In the event shareholders have not received application forms please contact the share registry Link Market Services:

[enquiries@linkmarketservices.co.nz](mailto:enquiries@linkmarketservices.co.nz) T 64 9 375 5998 or the Company Secretary, contact details below.

This announcement has been approved by the Board.

### Ends

Guy Robertson  
Company Secretary  
Tel: +61 407 983 270  
Email: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Dr Beata Edling  
Chief Executive Officer  
[beataedling@truscreen.com](mailto:beataedling@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

Julia Maguire  
Investor Relations  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

### About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical cancer screening programmes and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/)